The Evaluate Vantage team has rounded up our Top 10 Most-Read stories. Get up to speed on the big issues that have captured the interest and attention of your peers and competitors. Do you know why China-based companies traded on US exchanges are coming under pressure, what’s next for genetic medicine groups, and which new […]
Share:
The Evaluate Vantage team has rounded up our Top 10 Most-Read stories. Get up to speed on the big issues that have captured the interest and attention of your peers and competitors.
Do you know why China-based companies traded on US exchanges are coming under pressure, what’s next for genetic medicine groups, and which new product launches have the largest commercial potential? Get the answers to these and other pressing questions in this new article pack from Evaluate Vantage.
By 2032, the global pharmaceutical market is forecast to reach almost $1.9tn. Inside the innovations, dealmaking, and portfolio strategies transforming the global biopharma pipeline.
